Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex

EMBO Journal

Volumn 28, Issue 16, 2009, Pages 2469-2478

  Janssen, Bert J C ^a,e   Gomes, Lucio ^a   Koning, Roman I ^b   Svergun, Dmitri I ^c   Koster, Abraham J ^b   Fritzinger, David C ^d   Vogel, Carl Wilhelm ^d   Gros, Piet ^a,f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Complement system; Convertase; Immunology; Protein complex; Structure

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; METAL ION; PROTEIN VON WILLEBRAND FACTOR A; PROTEINASE; SNAKE VENOM; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEMENT SYSTEM; CRYSTAL STRUCTURE; ELECTRON MICROSCOPY; GENE MUTATION; MUTAGENESIS; OPTICAL RESOLUTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; RADIATION SCATTERING;

ANIMALS; CELL LINE; COBRA; COBRA VENOMS; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT FACTOR B; CRYSTALLOGRAPHY, X-RAY; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY;

EID: 69249220131     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/emboj.2009.184     Document Type: Article

References (61)

1. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC (2002) PHENIX: building new software for automated crystal-lographic structure determination. Acta Crystallogr D Biol Crystallogr 58: 1948-1954
2. Bhattacharya AA, Lupher Jr ML, Staunton DE, Liddington RC (2004) Crystal structure of the A domain from complement factor B reveals an integrin-like open conformation. Structure (Camb) 12: 371-378
3. CCP4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763
4. Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30: E9
5. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132
6. Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62: 72-82
7. Fishelson Z, Pangburn MK, Muller-Eberhard HJ (1984) Characterization of the initial C3 convertase of the alternative pathway of human complement. J Immunol 132: 1430-1434
8. Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V et al (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948-4952
9. Fritzinger DC, Bredehorst R, Vogel CW (1994) Molecular cloning and derived primary structure of cobra venom factor. Proc Natl Acad Sci USA 91: 12775-12779
10. Fritzinger DC, Hew BE, Thorne M, Pangburn MK, Janssen BJ, Gros P, Vogel CW (2009) Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Dev Comp Immunol 33: 105-116
11. Glaser F, Rosenberg Y, Kessel A, Pupko T, Ben-Tal N (2005) The ConSurf-HSSP database: the mapping of evolutionary conservation among homologs onto PDB structures. Proteins 58: 610-617
12. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, Lopez-Trascasa M, Sanchez-Corral P, Morgan BP, Rodriguez de Cordoba S (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 104: 240-245
13. Gowda DC, Petrella EC, Raj TT, Bredehorst R, Vogel CW (1994) Immunoreactivity and function of oligosaccharides in cobra venom factor. J Immunol 152: 2977-2986
14. Harris CL, Abbott RJ, Smith RA, Morgan BP, Lea SM (2005) Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). 3 Biol Chem 280: 2569-2578
15. Hensley P, O'Keefe MC, Spangler CJ, Osborne Jr JC, Vogel CW (1986) The effects of metal ions and temperature on the interaction of cobra venom factor and human complement factor B. J Biol Chem 261:11038-11044
16. Hinshelwood J, Perkins SJ (2000a) Conformational changes during the assembly of factor B from its domains by (1)H NMR spectroscopy and molecular modelling: their relevance to the regulation of factor B activity. J Mol Biol 301:1267-1285
17. Hinshelwood J, Perkins SJ (2000b) Metal-dependent conformational changes in a recombinant vWF-A domain from human factor B: a solution study by circular dichroism, fourier transform infrared and (1)H NMR spectroscopy. J Mol Biol 298: 135-147
18. Hinshelwood J, Spencer DI, Edwards YJ, Perkins SJ (1999) Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser deso-rption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B. J Mol Biol 294: 587-599
19. Hourcade DE, Mitchell L, Kuttner-Kondo LA, Atkinson JP, Medof ME (2002) Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb. J Biol Chem 277: 1107-1112
20. Hourcade DE, Mitchell LM, Oglesby TJ (1999) Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding. J Immunol 162: 2906-2911
21. Hourcade DE, Wagner LM, Oglesby TJ (1995) Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis. J Biol Chem 270: 19716-19722
22. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P (2006) Structure of C3b reveals conformational changes that underlie complement activity. Nature 444: 213-216
23. Janssen BJ, Halff EF, Lambris JD, Gros P (2007) Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem 282: 29241-29247
24. Janssen BJ, Huizinga EG, Raaijmakers HC, Roos A, Daha MR, Nilsson-Ekdahl K, Nilsson B, Gros P (2005) Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 437: 505-511
25. Kolln J, Bredehorst R, Spillner E (2005) Engineering of human complement component C3 for catalytic inhibition of complement. Immunol Lett 98: 49-56
26. Konarev PV, Volkov VV, Sokolova AV, Koch MH, Svergun DI (2003) PRIMUS:a Windows PC-based system for small-angle scattering data analysis. J Appl Cryst 36: 1277-1282
27. Krishnan V, Ponnuraj K, Xu Y, Macon K, Volanakis JE, Narayana SV (2009) The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb. Structure 17: 611-619
28. Leslie AG (1992) Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 26
29. Ludtke SJ, Baldwin PR, Chiu W (1999) EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol 128: 82-97
30. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Cryst 40: 658-674
31. Milder FJ, Gomes L, Schouten A, Janssen BJ, Huizinga EG, Romijn RA, Hemrika W, Roos A, Daha MR, Gros P (2007) Factor B structure provides insights into activation of the central protease of the complement system. Nat Struct Mol Biol 14: 224-228
32. Muller-Eberhard HJ (1988) Molecular organization and function of the complement system. Annu Rev Biochem 57: 321-347
33. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macro-molecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255
34. Nishida N, Walz T, Springer TA (2006) Structural transitions of complement component C3 and its activation products. Proc Natl Acad Sci USA 103: 19737-19742
35. O'Keefe MC, Caporale LH, Vogel CW (1988) A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor. J Biol Chem 263: 12690-12697
36. Ohi M, Li Y Cheng Y Walz T (2004) Negative staining and image classification - powerful tools in modern electron microscopy. Biol Proced Online 6: 23-34
37. Pangburn MK (1986) Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. J Immunol 136: 2216-2221
38. Perrakis A, Morris R, Lamzin VS (1999) Automated protein model building combined with iterative structure refinement. Nat Struct Biol 6: 458-463
39. Ponnuraj K, Xu Y Macon K, Moore D, Volanakis JE, Narayana SV (2004) Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell 14: 17-28
40. Pryzdial EL, Isenman DE (1987) Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact. J Biol Chem 262: 1519-1525
41. Reeves PJ, Callewaert N, Contreras R, Khorana HG (2002) Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracy-cline-inducible N- acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proc Natl Acad Sci USA 99:13419-13424
42. Ricklin D, Lambris JD (2007) Complement-targeted therapeutics. Nat Biotechnol 25: 1265-1275
43. Roessle MW, Klaering R, Ristau U, Robrahn B, Jahn D, Gehrmann T, Konarev PV, Round A, Friedler S, Hermes S, Svergun DI (2007) Upgrade of the small angle X-ray scattering Beamline X33 at the European Molecular Biology Laboratory, Hamburg. J Appl Cryst 40: S190-S194
44. Ross GD, Newman SL, Lambris JD, Devery-Pocius JE, Cain JA, Lachmann PJ (1983) Generation of three different fragments of bound C3 with purified factor I or serum. II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J Exp Med 158: 334-352
45. Scheres SH, Nunez-Ramirez R, Sorzano CO, Carazo JM, Marabini R (2008) Image processing for electron microscopy single-particle analysis using XMIPP. Nat Protoc 3: 977-990
46. Smith CA, Vogel CW, Muller-Eberhard HJ (1982) Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement. J Biol Chem 257: 9879-9882
47. Sorzano CO, Marabini R, Velazquez-Muriel J, Bilbao-Castro JR, Scheres SH, Carazo JM, Pascual-Montano A (2004) XMIPP: a new generation of an open-source image processing package for electron microscopy. J Struct Biol 148:194-204
48. Svergun DI, Barberato C, Koch MH (1995) CRYSOL - a program to evaluate X-ray solution scattering of biological macromolecules from atomic coordinates. J Appl Cryst 28: 768-773
49. Taniguchi-Sidle A, Isenman DE (1994) Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at the N-terminus of C3 alpha′-chain. J Immunol 153: 5285-5302
50. Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM (2005) A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol 42: 87-97
51. Torreira E, Tortajada A, Montes T, Rodriguez de Cordoba S, Llorca O (2009) 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase. Proc Natl Acad Sci USA 106: 882-887
52. Tuckwell DS, Xu Y, Newham P, Humphries MJ, Volanakis JE (1997) Surface loops adjacent to the cation-binding site of the complement factor B von Willebrand factor type A module determine C3b binding specificity. Biochemistry 36: 6605-6613
53. Vogel CW, Fritzinger DC (2007) Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion. Curr Pharm Des 13: 2916-2926
54. Vogel CW, Muller-Eberhard HJ (1982) The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J Biol Chem 257: 8292-8299
55. Vogel CW, Muller-Eberhard HJ (1984) Cobra venom factor: improved method for purification and biochemical characterization. J Immunol Methods 73: 203-220
56. Vogel CW, Smith CA, Muller-Eberhard HJ (1984) Cobra venom factor: structural homology with the third component of human complement. J Immunol 133: 3235-3241
57. Vogt W Dieminger L, Lynen R, Schmidt G (1974) Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement. Hoppe Seylers Z Physiol Chem 355:171-183
58. von Zabern I, Hinsch B, Przyklenk H, Schmidt G, Vogt W (1980) Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage. Immunobiology 157: 499-514
59. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344:1058-1066
60. Weiler JM, Daha MR, Austen KF, Fearon DT (1976) Control of the amplification convertase of complement by the plasma protein betalH. Proc Natl Acad Sci USA 73: 3268-3272
61. Wiesmann C, Katschke KJ, Yin J, Helmy KY, Steffek M, Fairbrother WJ, McCallum SA, Embuscado L, DeForge L, Hass PE, van Lookeren Campagne M (2006) Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444: 217-220